IBD therapeutics: what is in the pipeline?
Frontline Gastroenterol
; 13(e1): e35-e43, 2022.
Article
em En
| MEDLINE
| ID: mdl-35812030
ABSTRACT
Inflammatory bowel disease (IBD) is an idiopathic long-term relapsing and remitting disorder including ulcerative colitis and Crohn's disease. The aim of therapy is to induce and maintain remission. Anti-TNF therapies dramatically improved clinical outcomes but primary failure or secondary loss is a common problem as well as potential side effects potentially limiting efficacy and long-term use. The advent of new targeted agents with the potential for greater safety is welcomed in IBD and offers the potential for different agents as the disease becomes refractory or even combination therapies to maximise effectiveness without compromising safety in the future. More data are required to understand the best positioning in pathways and longer-term safety effects.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Revista:
Frontline Gastroenterol
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Reino Unido